Adrenocortical carcinoma: Past, present, and future

Journal of Surgical Oncology

Volumn 106, Issue 5, 2012, Pages 586-594

  Lafemina, Jennifer ^a   Brennan, Murray F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adrenocortical carcinoma; management; outcomes

Indexed keywords

17 OXOSTEROID; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUDROCORTISONE; HYDROCORTISONE; MITOTANE; STEROID; STREPTOZOCIN;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ANEMIA; ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CUSHING SYNDROME; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMINIZATION; FEVER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; METASTASIS RESECTION; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRILIZATION; VOMITING; WEIGHT REDUCTION;

ADRENAL CORTEX NEOPLASMS; HUMANS;

EID: 84866431384     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23112     Document Type: Review

References (94)

1. Brennan MF:, Adrenocortical carcinoma. CA Cancer J Clin 1987; 37: 348-365. (Pubitemid 18026218)
2. Lubitz JA, Freeman L, Okun R:, Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223: 1109-1112.
3. Barzon L, Sonino N, Fallo F, et al.: Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285. (Pubitemid 37304697)
4. Murphy MM, Witkowski ER, Ng SC, et al.: Trends in adrenalectomy: A recent national review. Surg Endosc 2010; 24: 2518-2526.
5. nd edition. Philadelphia: Lippincott-Raven; 1997. pp. 1192-1206.
6. Pommier RF, Brennan MF:, An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-970; discussion 970-961.
7. Schulick RD, Brennan MF:, Adrenocortical carcinoma. World J Urol 1999; 17: 26-34.
8. Schulick RD, Brennan MF:, Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6: 719-726. (Pubitemid 30013647)
9. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al.: Adrenocortical carcinoma: Clinical and laboratory observations. Cancer 2000; 88: 711-736. (Pubitemid 30091090)
10. Michalkiewicz E, Sandrini R, Figueiredo B, et al.: Clinical and outcome characteristics of children with adrenocortical tumors: A report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22: 838-845. (Pubitemid 41103595)
11. Ribeiro RC, Sandrini F, Figueiredo B, et al.: An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001; 98: 9330-9335. (Pubitemid 32743916)
12. Icard P, Goudet P, Charpenay C, et al.: Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25: 891-897. (Pubitemid 32666390)
13. Wooten MD, King DK:, Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-3155. (Pubitemid 23356754)
14. Allolio B, Fassnacht M:, Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab 2006; 91: 2027-2037. (Pubitemid 43854976)
15. Bilimoria KY, Shen WT, Elaraj D, et al.: Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136.
16. Cohn K, Gottesman L, Brennan M:, Adrenocortical carcinoma. Surgery 1986; 100: 1170-1177. (Pubitemid 17223238)
17. Kjellman M, Roshani L, Teh BT, et al.: Genotyping of adrenocortical tumors: Very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab 1999; 84: 730-735. (Pubitemid 29075713)
18. Gicquel C, Bertagna X, Gaston V, et al.: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001; 61: 6762-6767. (Pubitemid 32896498)
19. Libe R, Fratticci A, Bertherat J:, Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 2007; 14: 13-28. (Pubitemid 47521719)
20. Sidhu S, Marsh DJ, Theodosopoulos G, et al.: Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002; 87: 3467-3474. (Pubitemid 34816405)
21. Gicquel C, Raffin-Sanson ML, Gaston V, et al.: Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: Study on a series of 82 tumors. J Clin Endocrinol Metab 1997; 82: 2559-2565. (Pubitemid 27337873)
22. Berruti A, Ferrero A, Sperone P, et al.: Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs 2008; 13: 497-509.
23. Macfarlane DA:, Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23: 155-186.
24. Sullivan M, Boileau M, Hodges CV:, Adrenal cortical carcinoma. J Urol 1978; 120: 660-665. (Pubitemid 9091388)
25. Jaques DP, Brennan MF,. Tumors of the adrenal cortex. In:, Cameron JL, editor. Current surgical therapy. Toronto: BC Decker; 1989. pp. 435-444.
26. Wandoloski M, Bussey KJ, Demeure MJ:, Adrenocortical cancer. Surg Clin North Am 2009; 89: 1255-1267.
27. Fassnacht M, Johanssen S, Quinkler M, et al.: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer 2009; 115: 243-250.
28. Eddy RL, Jones AL, Gilliland PF, et al.: Cushing's syndrome: A prospective study of diagnostic methods. Am J Med 1973; 55: 621-630.
29. Grumbach MM, Biller BM, Braunstein GD, et al.: Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003; 138: 424-429. (Pubitemid 36262654)
30. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 2002; 19: 1-25.
31. Boland GW, Lee MJ, Gazelle GS, et al.: Characterization of adrenal masses using unenhanced CT: An analysis of the CT literature. AJR Am J Roentgenol 1998; 171: 201-204. (Pubitemid 28308675)
32. Szolar DH, Kammerhuber FH:, Adrenal adenomas and nonadenomas: Assessment of washout at delayed contrast-enhanced CT. Radiology 1998; 207: 369-375. (Pubitemid 28259051)
33. Szolar DH, Korobkin M, Reittner P, et al.: Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234: 479-485. (Pubitemid 40139919)
34. Pena CS, Boland GW, Hahn PF, et al.: Characterization of indeterminate (lipid-poor) adrenal masses: Use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217: 798-802.
35. Honigschnabl S, Gallo S, Niederle B, et al.: How accurate is MR imaging in characterisation of adrenal masses: Update of a long-term study. Eur J Radiol 2002; 41: 113-122. (Pubitemid 34164132)
36. Bilbey JH, McLoughlin RF, Kurkjian PS, et al.: MR imaging of adrenal masses: Value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR Am J Roentgenol 1995; 164: 637-642.
37. Heinz-Peer G, Honigschnabl S, Schneider B, et al.: Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol 1999; 173: 15-22. (Pubitemid 29291081)
38. Korobkin M, Lombardi TJ, Aisen AM, et al.: Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995; 197: 411-418.
39. Metser U, Miller E, Lerman H, et al.: 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006; 47: 32-37. (Pubitemid 46768509)
40. Blake MA, Slattery JM, Kalra MK, et al.: Adrenal lesions: Characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006; 238: 970-977. (Pubitemid 43289929)
41. Bergstrom M, Juhlin C, Bonasera TA, et al.: PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 2000; 41: 275-282. (Pubitemid 30091347)
42. Khan TS, Sundin A, Juhlin C, et al.: 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003; 30: 403-410. (Pubitemid 36692866)
43. Minn H, Salonen A, Friberg J, et al.: Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 2004; 45: 972-979. (Pubitemid 47611684)
44. Zettinig G, Mitterhauser M, Wadsak W, et al.: Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 2004; 31: 1224-1230. (Pubitemid 39222485)
45. Mitchell IC, Nwariaku FE:, Adrenal masses in the cancer patient: Surveillance or excision. Oncologist 2007; 12: 168-174.
46. Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004; 60: 273-287. (Pubitemid 38297116)
47. de Reynies A, Assie G, Rickman DS, et al.: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27: 1108-1115.
48. Herbet M, Feige JJ, Thomas M:, Insights into the role of genetic alterations in adrenocortical tumorigenesis. Mol Cell Endocrinol 2009; 300: 169-174.
49. Balasubramaniam S, Fojo T:, Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol 2010; 37: 619-626.
50. Patterson EE, Holloway AK, Weng J, et al.: MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117: 1630-1639.
51. Fernandez-Ranvier GG, Weng J, Yeh RF, et al.: Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg 2008; 143: 841-846; discussion 846.
52. Stojadinovic A, Ghossein RA, Hoos A, et al.: Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20: 941-950. (Pubitemid 34141836)
53. Rapaport E, Goldberg MB, Gordan GS, et al. Mortality in surgically treated adrenocortical tumors. II. Review of cases reported for the 20 year period 1930-1949, inclusive. Postgrad Med 1952; 11: 325-353.
54. Simkin B:, Long-term management of patients after adrenalectomy. Calif Med 1957; 87: 383-388.
55. Hedican SP, Marshall FF:, Adrenocortical carcinoma with intracaval extension. J Urol 1997; 158: 2056-2061. (Pubitemid 27481326)
56. Javadpour N, Woltering EA, McIntosh CL:, Thoracoabdominal-median sternotomy for resection of primary adrenal carcinoma extending into inferior vena cava and hepatic vein. Urology 1978; 12: 626-627.
57. Moul JW, Hardy MR, McLeod DG:, Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection. Urology 1991; 38: 179-183.
58. Brunt LM, Doherty GM, Norton JA, et al.: Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. J Am Coll Surg 1996; 183: 1-10. (Pubitemid 26234887)
59. Hallfeldt KK, Mussack T, Trupka A, et al.: Laparoscopic lateral adrenalectomy versus open posterior adrenalectomy for the treatment of benign adrenal tumors. Surg Endosc 2003; 17: 264-267. (Pubitemid 36173279)
60. Lee J, El-Tamer M, Schifftner T, et al.: Open and laparoscopic adrenalectomy: Analysis of the National Surgical Quality Improvement Program. J Am Coll Surg 2008; 206: 953-959; discussion 959-961.
61. MacGillivray DC, Shichman SJ, Ferrer FA, et al. A comparison of open vs laparoscopic adrenalectomy. Surg Endosc 1996; 10: 987-990. (Pubitemid 126474825)
62. Brix D, Allolio B, Fenske W, et al.: Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: Surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58: 609-615.
63. Didolkar MS, Bescher RA, Elias EG, et al. Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-2161. (Pubitemid 11098583)
64. Martz F, Straw JA:, The in vitro metabolism of 1-(o-chlorophenyl)-1-(p- chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: A possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos 1977; 5: 482-486. (Pubitemid 8319397)
65. Bergenstal DM, Lipsett M, Moy R.N, et al.: Regression of adrenal: Adrenal function in man by o, p'-DDD. Trans Assoc Am Physicians 1959; 72: 341-350.
66. Lindhe O, Skogseid B, Brandt I:, Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. J Clin Endocrinol Metab 2002; 87: 1319-1326. (Pubitemid 36121104)
67. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al.: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71: 3119-3123. (Pubitemid 23145548)
68. Terzolo M, Angeli A, Fassnacht M, et al.: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380. (Pubitemid 46883771)
69. Grubbs EG, Callender GG, Xing Y, et al.: Recurrence of adrenal cortical carcinoma following resection: Surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 2010; 17: 263-270.
70. Khan TS, Imam H, Juhlin C, et al.: Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol 2000; 11: 1281-1287.
71. Bukowski RM, Wolfe M, Levine HS, et al.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study. J Clin Oncol 1993; 11: 161-165. (Pubitemid 23059990)
72. Bonacci R, Gigliotti A, Baudin E, et al.: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998; 78: 546-549. (Pubitemid 28360647)
73. Gonzalez RJ, Tamm EP, Ng C, et al.: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery 2007; 142: 867-875 discussion 867-875. (Pubitemid 350193248)
74. Haq MM, Legha SS, Samaan NA, et al.: Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980; 64: 909-913. (Pubitemid 11139829)
75. Tattersall MH, Lander H, Bain B, et al.: Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1980; 1: 419-421. (Pubitemid 10002849)
76. Chun HG, Yagoda A, Kemeny N, et al. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 1983; 67: 513-514. (Pubitemid 13106698)
77. Abraham J, Bakke S, Rutt A, et al.: A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94: 2333-2343. (Pubitemid 34457113)
78. Berruti A, Terzolo M, Sperone P, et al.: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657-666. (Pubitemid 41482999)
79. Veytsman I, Nieman L, Fojo T:, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 27: 4619-4629.
80. Fassnacht M, Hahner S, Polat B, et al.: Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91: 4501-4504. (Pubitemid 44833430)
81. Polat B, Fassnacht M, Pfreundner L, et al.: Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115: 2816-2823.
82. Cazejust J, De Baere T, Auperin A, et al.: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 2010; 21: 1527-1532.
83. Soga H, Takenaka A, Ooba T, et al.: A twelve-year experience with adrenal cortical carcinoma in a single institution: Long-term survival after surgical treatment and transcatheter arterial embolization. Urol Int 2009; 82: 222-226.
84. Scagliotti GV, Novello S:, The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2011; Epub ahead of print.
85. Sachdev D, Yee D:, Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6: 1-12. (Pubitemid 46206663)
86. Haluska P, Worden F, Olmos D, et al.: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65: 765-773.
87. Naing A, Kurzrock R, Burger A, et al.: Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011; 17: 6052-6060.
88. Mistry P, Stewart AJ, Dangerfield W, et al.: In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-758. (Pubitemid 32128642)
89. Walker J, Martin C, Callaghan R:, Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 2004; 40: 594-605. (Pubitemid 38220779)
90. Decker RA, Elson P, Hogan TF, et al.: Eastern cooperative oncology group study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991; 110: 1006-1013.
91. Haak HR, Hermans J, van de Velde CJ, et al.: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951. (Pubitemid 24140681)
92. Barzon L, Fallo F, Sonino N, et al.: Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54: 490-496. (Pubitemid 27470260)
93. Williamson SK, Lew D, Miller GJ, et al.: Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A southwest oncology group study. Cancer 2000; 88: 1159-1165. (Pubitemid 30127678)
94. Baudin E, Pellegriti G, Bonnay M, et al.: Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92: 1385-1392. (Pubitemid 32947821)